ABEONA THERAPEUTICS INC.
Income Statement
| Line Item | FY2025 | FY2023 | FY2022 | FY2021 | FY2020 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.8M | $3.5M | $1.4M | $3.0M | $10.0M | $3.0M | $837.0K | $889.0K |
| Cost of Revenue | $1.5M | — | — | — | — | — | — | — |
| Gross Profit | $4.3M | — | — | — | — | — | — | — |
| Gross Margin | 73.7% | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $26.8M | $31.1M | $29.0M | $38.7M | $30.1M | $38.7M | $17.0M | $10.7M |
| SG&A Expense | $65.0M | $19.0M | $17.3M | $21.6M | $23.8M | $20.1M | $10.9M | $13.3M |
| Operating Income | $-89.4M | $-47.1M | $-50.9M | $-89.8M | $-81.4M | $-58.2M | $-27.8M | $-23.9M |
| Operating Margin | -1,536.9% | -1,346.7% | -3,600.8% | -2,994.5% | -814.2% | -1,940.2% | -3,325.7% | -2,686.3% |
| Interest Expense | $3.7M | $418.0K | $736.0K | $3.7M | $4.1M | — | — | — |
| Pretax Income | $71.3M | — | — | — | — | — | — | — |
| Income Tax Expense | $100.0K | — | — | — | — | $0 | $0 | $0 |
| Net Income | $71.2M | $-54.2M | $-39.7M | $-84.9M | $-84.2M | $-56.7M | $-27.3M | $-21.9M |
| Net Margin | 1,223.1% | -1,548.2% | -2,807.4% | -2,831.2% | -842.3% | -1,890.3% | -3,263.9% | -2,460.4% |
| EPS (Basic) | $1.34 | $-2.53 | $-1.84 | $-7.19 | $-0.30 | $-0.40 | $-0.22 | $-0.21 |
| EPS (Diluted) | $1.01 | $-2.53 | $-1.84 | $-0.29 | $-0.30 | $-0.40 | $-0.22 | $-0.21 |
| Shares Outstanding (Basic) | 53.0M | 21.4M | 23.6M | 11.8M | 288.4M | 143.8M | 140.7M | 102.5M |
| Shares Outstanding (Diluted) | 66.1M | 21.4M | 23.6M | 11.8M | 288.4M | 143.8M | 140.7M | 102.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |